Jane Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jane Yang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Steven A. Prescott
Neurosciences and Mental Health, The Hospital for Sick Children
7 shared publications - Stéphanie Ratté
The Hospital for Sick Children
6 shared publications - Yu-Feng Xie
Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada
4 shared publications - Sarah N. Wright
Department of Medicine, University of California, San Diego, La Jolla, USA
2 shared publications Arianna Colini Baldeschi
1 shared publicationErin Schiksnis
1 shared publication
Latest Publications
- Open Access
Redefining Parkinson's Disease by Dysregulated Genetic Networks in Distinct Cell Types
Parkinson's disease (PD) is classically linked to dopaminergic neuron loss, but emerging evidence suggests broader cellular involvement. Here we show that PD risk variants converge on distinct molecular networks across specific brain cell types, enabling stratification of patients into six subgroups: dopaminergic, oligodendrocyte progenitor cells (O), excitatory (E), dopaminergic/excitatory, dopaminergic/oligodendrocyte and other. While all subgroups exhibit motor symptoms, the E-group individuals also display more severe non-motor symptoms, including dementia, hyposmia, and REM sleep behavior disorder. The O-group individuals exhibit reduced myelin integrity, as demonstrated by diffusion tensor imaging, implicating NRG6 (formerly C1orf56), a previously uncharacterized high-risk PD gene. We show that NRG6 encodes a conserved epidermal growth factor-like domain structurally and functionally analogous to neuregulin-1, which is critical for oligodendrocyte development and myelination. These findings redefine the cellular architecture of PD vulnerability and identify neuregulin-like signaling in oligodendrocytes as a potential contributor to non-motor symptoms.
Open AccessRedefining Parkinson's Disease by Dysregulated Genetic Networks in Distinct Cell Types
Parkinson's disease (PD) is classically linked to dopaminergic neuron loss, but emerging evidence suggests broader cellular involvement. Here we show that PD risk variants converge on distinct molecular networks across specific brain cell types, enabling stratification of patients into six subgroups: dopaminergic, oligodendrocyte progenitor cells (O), excitatory (E), dopaminergic/excitatory, dopaminergic/oligodendrocyte and other. While all subgroups exhibit motor symptoms, the E-group individuals also display more severe non-motor symptoms, including dementia, hyposmia, and REM sleep behavior disorder. The O-group individuals exhibit reduced myelin integrity, as demonstrated by diffusion tensor imaging, implicating NRG6 (formerly C1orf56), a previously uncharacterized high-risk PD gene. We show that NRG6 encodes a conserved epidermal growth factor-like domain structurally and functionally analogous to neuregulin-1, which is critical for oligodendrocyte development and myelination. These findings redefine the cellular architecture of PD vulnerability and identify neuregulin-like signaling in oligodendrocytes as a potential contributor to non-motor symptoms.
- Open Access
Common and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene mutational constraints, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
Open AccessCommon and rare genetic variants show network convergence for a majority of human traits
While both common and rare variants contribute to the genetic etiology of complex traits, whether their impacts manifest through the same effector genes and molecular mechanisms is not well understood. Here, we systematically analyze common and rare variants associated with each of 373 phenotypic traits within a large biological knowledge network of gene and protein interactions. While common and rare variants implicate few shared genes, they converge on shared molecular networks for more than 75% of traits. We demonstrate that the strength of this convergence is influenced by core factors such as trait heritability, gene mutational constraints, and tissue specificity. Using neuropsychiatric traits as examples, we show that common and rare variants impact shared functions across multiple levels of biological organization. These findings underscore the importance of integrating variants across the frequency spectrum and establish a foundation for network-based investigations of the genetics of diverse human diseases and phenotypes.
- Open Access
- 23 October 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 166  (3) , 481-501
Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain
The voltage-gated sodium channel NaV1.7 plays an important role in pain processing according to genetic data. Those data made NaV1.7 a popular drug target, especially since its relatively selective expression in nociceptors promised pain relief without the adverse effects associated with broader sodium channel blockade. Despite encouraging preclinical data in rodents, NaV1.7-selective inhibitors have not yet proven effective in clinical trials. Discrepancies between preclinical and clinical results should raise alarms. We reviewed preclinical and clinical reports on the analgesic efficacy of NaV1.7-selective inhibitors and found critical differences in several factors. Putting aside species differences, most preclinical studies tested young male rodents with limited genetic variability, inconsistent with the clinical population. Inflammatory pain was the most common preclinical chronic pain model whereas nearly all clinical trials focused on neuropathic pain despite some evidence suggesting NaV1.7 channels are not essential for neuropathic pain. Preclinical studies almost exclusively measured evoked pain whereas most clinical trials assessed average pain intensity without distinguishing between evoked and spontaneous pain. Nearly all preclinical studies gave a single dose of drug unlike the repeat dosing used clinically, thus precluding preclinical data from demonstrating whether tolerance or other slow processes occur. In summary, preclinical testing of NaV1.7-selective inhibitors aligned poorly with clinical testing. Beyond issues that have already garnered widespread attention in the pain literature, our results highlight the treatment regimen and choice of pain model as areas for improvement.
- 23 October 2024
- Published by Wolters Kluwer Health in Pain
- Vol. 166  (3) , 481-501
Open AccessDiscordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain
The voltage-gated sodium channel NaV1.7 plays an important role in pain processing according to genetic data. Those data made NaV1.7 a popular drug target, especially since its relatively selective expression in nociceptors promised pain relief without the adverse effects associated with broader sodium channel blockade. Despite encouraging preclinical data in rodents, NaV1.7-selective inhibitors have not yet proven effective in clinical trials. Discrepancies between preclinical and clinical results should raise alarms. We reviewed preclinical and clinical reports on the analgesic efficacy of NaV1.7-selective inhibitors and found critical differences in several factors. Putting aside species differences, most preclinical studies tested young male rodents with limited genetic variability, inconsistent with the clinical population. Inflammatory pain was the most common preclinical chronic pain model whereas nearly all clinical trials focused on neuropathic pain despite some evidence suggesting NaV1.7 channels are not essential for neuropathic pain. Preclinical studies almost exclusively measured evoked pain whereas most clinical trials assessed average pain intensity without distinguishing between evoked and spontaneous pain. Nearly all preclinical studies gave a single dose of drug unlike the repeat dosing used clinically, thus precluding preclinical data from demonstrating whether tolerance or other slow processes occur. In summary, preclinical testing of NaV1.7-selective inhibitors aligned poorly with clinical testing. Beyond issues that have already garnered widespread attention in the pain literature, our results highlight the treatment regimen and choice of pain model as areas for improvement.
- Open Access
- 30 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel NaV1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but clinical trials seeking to treat pain by inhibiting NaV1.7 pharmacologically have struggled. This may reflect the variable contribution of NaV1.7 to nociceptor excitability. Contrary to claims that NaV1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve similar excitability using different combinations of NaV1.3, NaV1.7, and NaV1.8. Selectively blocking one of those NaV subtypes reduces nociceptor excitability only if the other subtypes are weakly expressed. For example, excitability relies on NaV1.8 in acutely dissociated nociceptors but responsibility shifts to NaV1.7 and NaV1.3 by the fourth day in culture. A similar shift in NaV dependence occurs in vivo after inflammation, impacting ability of the NaV1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different NaV subtypes exemplifies degeneracy – achieving similar function using different components – and compromises reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant NaV subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level.
- 30 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessSimilar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel NaV1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but clinical trials seeking to treat pain by inhibiting NaV1.7 pharmacologically have struggled. This may reflect the variable contribution of NaV1.7 to nociceptor excitability. Contrary to claims that NaV1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve similar excitability using different combinations of NaV1.3, NaV1.7, and NaV1.8. Selectively blocking one of those NaV subtypes reduces nociceptor excitability only if the other subtypes are weakly expressed. For example, excitability relies on NaV1.8 in acutely dissociated nociceptors but responsibility shifts to NaV1.7 and NaV1.3 by the fourth day in culture. A similar shift in NaV dependence occurs in vivo after inflammation, impacting ability of the NaV1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different NaV subtypes exemplifies degeneracy – achieving similar function using different components – and compromises reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant NaV subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level.
- Open Access
- 8 April 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Equivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel NaV1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but efforts to treat pain by inhibiting NaV1.7 pharmacologically have largely failed. This may reflect the variable contribution of NaV1.7 to nociceptor excitability. Contrary to claims that NaV1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve equivalent excitability using different combinations of NaV1.3, NaV1.7, and NaV1.8. Selectively blocking one of those NaV subtypes reduces nociceptor excitability only if the other two subtypes are weakly expressed. For example, excitability relies on NaV1.8 in acutely dissociated nociceptors but responsibility shifts to NaV1.7 and NaV1.3 by the fourth day in culture. A similar shift in NaV dependence occurs in vivo after inflammation, impacting ability of the NaV1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different NaV subtypes exemplifies degeneracy – equivalent function using different components – and compromises the reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant NaV subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level.
- 8 April 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessEquivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel NaV1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but efforts to treat pain by inhibiting NaV1.7 pharmacologically have largely failed. This may reflect the variable contribution of NaV1.7 to nociceptor excitability. Contrary to claims that NaV1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve equivalent excitability using different combinations of NaV1.3, NaV1.7, and NaV1.8. Selectively blocking one of those NaV subtypes reduces nociceptor excitability only if the other two subtypes are weakly expressed. For example, excitability relies on NaV1.8 in acutely dissociated nociceptors but responsibility shifts to NaV1.7 and NaV1.3 by the fourth day in culture. A similar shift in NaV dependence occurs in vivo after inflammation, impacting ability of the NaV1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different NaV subtypes exemplifies degeneracy – equivalent function using different components – and compromises the reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant NaV subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level.
- Open Access
Equivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel Na V 1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but efforts to treat pain by inhibiting Na V 1.7 pharmacologically have largely failed. This may reflect the variable contribution of Na V 1.7 to nociceptor excitability. Contrary to claims that Na V 1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve equivalent excitability using different combinations of Na V 1.3, Na V 1.7, and Na V 1.8. Selectively blocking one of those Na V subtypes reduces nociceptor excitability only if the other two subtypes are weakly expressed. For example, excitability relies on Na V 1.8 in acutely dissociated nociceptors but responsibility shifts to Na V 1.7 and Na V 1.3 by the fourth day in culture. A similar shift in Na V dependence occurs in vivo after inflammation, impacting ability of the Na V 1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different Na V subtypes exemplifies degeneracy – equivalent function using different components – and compromises the reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant Na V subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level. SIGNIFICANCE STATEMENT: Nociceptors can achieve equivalent excitability using different sodium channel subtypes. The analgesic efficacy of subtype-selective drugs hinges on which subtype controls excitability. This contingency likely contributes to poor clinical outcomes.
Open AccessEquivalent excitability through different sodium channels and implications for the analgesic efficacy of selective drugs
Nociceptive sensory neurons convey pain-related signals to the CNS using action potentials. Loss-of-function mutations in the voltage-gated sodium channel Na V 1.7 cause insensitivity to pain (presumably by reducing nociceptor excitability) but efforts to treat pain by inhibiting Na V 1.7 pharmacologically have largely failed. This may reflect the variable contribution of Na V 1.7 to nociceptor excitability. Contrary to claims that Na V 1.7 is necessary for nociceptors to initiate action potentials, we show that nociceptors can achieve equivalent excitability using different combinations of Na V 1.3, Na V 1.7, and Na V 1.8. Selectively blocking one of those Na V subtypes reduces nociceptor excitability only if the other two subtypes are weakly expressed. For example, excitability relies on Na V 1.8 in acutely dissociated nociceptors but responsibility shifts to Na V 1.7 and Na V 1.3 by the fourth day in culture. A similar shift in Na V dependence occurs in vivo after inflammation, impacting ability of the Na V 1.7-selective inhibitor PF-05089771 to reduce pain in behavioral tests. Flexible use of different Na V subtypes exemplifies degeneracy – equivalent function using different components – and compromises the reliable modulation of nociceptor excitability by subtype-selective inhibitors. Identifying the dominant Na V subtype to predict drug efficacy is not trivial. Degeneracy at the cellular level must be considered when choosing drug targets at the molecular level. SIGNIFICANCE STATEMENT: Nociceptors can achieve equivalent excitability using different sodium channel subtypes. The analgesic efficacy of subtype-selective drugs hinges on which subtype controls excitability. This contingency likely contributes to poor clinical outcomes.
- Open Access
- 11 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119  (20)
TRPC4 and GIRK channels underlie neuronal coding of firing patterns that reflect Gq/11–Gi/ocoincidence signals of variable strengths
Significance: Neurons communicate by releasing neurotransmitters, many of which act at G protein–coupled receptors. Although it is well known that Gq/11accelerates action potential firing while Gi/oinhibits firing, how firing patterns change in response to simultaneous activation of Gq/11and Gi/oremains elusive, especially because the relative strength of Gq/11versus Gi/oactivation varies greatly from event to event. This study reveals that neurons encode distinct messages that reflect coincident Gq/11and Gi/ostimulation by activating two ion channels, TRPC4 and GIRK. The resulting firing patterns, composed of burst, pause, and firing recovery phases, reflect both the occurrence of coincident Gq/11and Gi/oactivation and their relative strengths. With these, we may begin to interpret the language of neurons.
- 11 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119  (20)
Open AccessTRPC4 and GIRK channels underlie neuronal coding of firing patterns that reflect Gq/11–Gi/ocoincidence signals of variable strengths
Significance: Neurons communicate by releasing neurotransmitters, many of which act at G protein–coupled receptors. Although it is well known that Gq/11accelerates action potential firing while Gi/oinhibits firing, how firing patterns change in response to simultaneous activation of Gq/11and Gi/oremains elusive, especially because the relative strength of Gq/11versus Gi/oactivation varies greatly from event to event. This study reveals that neurons encode distinct messages that reflect coincident Gq/11and Gi/ostimulation by activating two ion channels, TRPC4 and GIRK. The resulting firing patterns, composed of burst, pause, and firing recovery phases, reflect both the occurrence of coincident Gq/11and Gi/oactivation and their relative strengths. With these, we may begin to interpret the language of neurons.
- Open Access
- 16 March 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Minimal requirements for a neuron to coregulate many properties and the implications for ion channel correlations and robustness
Neurons regulate their excitability by adjusting their ion channel levels. Degeneracy – achieving equivalent outcomes (excitability) using different solutions (channel combinations) – facilitates this regulation by enabling a disruptive change in one channel to be offset by compensatory changes in other channels. But neurons must coregulate many properties. Pleiotropy – the impact of one channel on more than one property – complicates regulation because a compensatory ion channel change that restores one property to its target value often disrupts other properties. How then does a neuron simultaneously regulate multiple properties? Here, we demonstrate that of the many channel combinations producing the target value for one property (the single-output solution set), few combinations produce the target value for other properties. Combinations producing the target value for two or more properties (the multioutput solution set) correspond to the intersection between single-output solution sets. Properties can be effectively coregulated only if the number of adjustable channels (nin) exceeds the number of regulated properties (nout). Ion channel correlations emerge during homeostatic regulation when the dimensionality of solution space (nin − nout) is low. Even if each property can be regulated to its target value when considered in isolation, regulation as a whole fails if single-output solution sets do not intersect. Our results also highlight that ion channels must be coadjusted with different ratios to regulate different properties, which suggests that each error signal drives modulatory changes independently, despite those changes ultimately affecting the same ion channels.
- 16 March 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessMinimal requirements for a neuron to coregulate many properties and the implications for ion channel correlations and robustness
Neurons regulate their excitability by adjusting their ion channel levels. Degeneracy – achieving equivalent outcomes (excitability) using different solutions (channel combinations) – facilitates this regulation by enabling a disruptive change in one channel to be offset by compensatory changes in other channels. But neurons must coregulate many properties. Pleiotropy – the impact of one channel on more than one property – complicates regulation because a compensatory ion channel change that restores one property to its target value often disrupts other properties. How then does a neuron simultaneously regulate multiple properties? Here, we demonstrate that of the many channel combinations producing the target value for one property (the single-output solution set), few combinations produce the target value for other properties. Combinations producing the target value for two or more properties (the multioutput solution set) correspond to the intersection between single-output solution sets. Properties can be effectively coregulated only if the number of adjustable channels (nin) exceeds the number of regulated properties (nout). Ion channel correlations emerge during homeostatic regulation when the dimensionality of solution space (nin − nout) is low. Even if each property can be regulated to its target value when considered in isolation, regulation as a whole fails if single-output solution sets do not intersect. Our results also highlight that ion channels must be coadjusted with different ratios to regulate different properties, which suggests that each error signal drives modulatory changes independently, despite those changes ultimately affecting the same ion channels.
- Open Access
Minimal requirements for a neuron to co-regulate many properties and the implications for ion channel correlations and robustness
Neurons regulate their excitability by adjusting their ion channel levels. Degeneracy – achieving equivalent outcomes (excitability) using different solutions (channel combinations) – facilitates this regulation by enabling a disruptive change in one channel to be offset by compensatory changes in other channels. But neurons must co-regulate many properties. Pleiotropy – the impact of one channel on more than one property – complicates regulation because a compensatory ion channel change that restores one property to its target value often disrupts other properties. How then does a neuron simultaneously regulate multiple properties? Here we demonstrate that of the many channel combinations producing the target value for one property (the single-output solution set), few combinations produce the target value for other properties. Combinations producing the target value for two or more properties (the multi-output solution set) correspond to the intersection between single-output solution sets. Properties can be effectively co-regulated only if the number of adjustable channels ( n in ) exceeds the number of regulated properties ( n out ). Ion channel correlations emerge during homeostatic regulation when the dimensionality of solution space ( n in – n out ) is low. Even if each property can be regulated to its target value when considered in isolation, regulation as a whole fails if single-output solution sets do not intersect. Our results also highlight that ion channels must be co-adjusted with different ratios to regulate different properties, which suggests that each error signal drives modulatory changes independently, despite those changes ultimately affecting the same ion channels.
Open AccessMinimal requirements for a neuron to co-regulate many properties and the implications for ion channel correlations and robustness
Neurons regulate their excitability by adjusting their ion channel levels. Degeneracy – achieving equivalent outcomes (excitability) using different solutions (channel combinations) – facilitates this regulation by enabling a disruptive change in one channel to be offset by compensatory changes in other channels. But neurons must co-regulate many properties. Pleiotropy – the impact of one channel on more than one property – complicates regulation because a compensatory ion channel change that restores one property to its target value often disrupts other properties. How then does a neuron simultaneously regulate multiple properties? Here we demonstrate that of the many channel combinations producing the target value for one property (the single-output solution set), few combinations produce the target value for other properties. Combinations producing the target value for two or more properties (the multi-output solution set) correspond to the intersection between single-output solution sets. Properties can be effectively co-regulated only if the number of adjustable channels ( n in ) exceeds the number of regulated properties ( n out ). Ion channel correlations emerge during homeostatic regulation when the dimensionality of solution space ( n in – n out ) is low. Even if each property can be regulated to its target value when considered in isolation, regulation as a whole fails if single-output solution sets do not intersect. Our results also highlight that ion channels must be co-adjusted with different ratios to regulate different properties, which suggests that each error signal drives modulatory changes independently, despite those changes ultimately affecting the same ion channels.